Difference between revisions of "Diabetes UK"

From Powerbase
Jump to: navigation, search
m
 
(8 intermediate revisions by 4 users not shown)
Line 1: Line 1:
Diabetes UK is the charity working for "people with diabetes, funding research, campaigning and helping people live with the condition. [...]We represent the interests of people with diabetes by lobbying the government for better standards of care and the best quality of life. Diabetes UK spends up to £6.5 million on research...".<ref>http://www.diabetes.org.uk/About_us/How-we-are-governed/Legal-and-financial-information/Report_and_financial_information/</ref>
+
Diabetes UK is a charity working for "people with diabetes, funding research, campaigning and helping people live with the condition. [...]We represent the interests of people with diabetes by lobbying the government for better standards of care and the best quality of life. Diabetes UK spends up to £6.5 million on research".<ref>http://www.diabetes.org.uk/About_us/How-we-are-governed/Legal-and-financial-information/Report_and_financial_information/</ref>
 
Diabetes UK uses services of [[Ipsos MORI]]<ref>http://www.diabetes.org.uk/Documents/About%20Us/Financial%20Statement06FINAL.pdf</ref>.
 
Diabetes UK uses services of [[Ipsos MORI]]<ref>http://www.diabetes.org.uk/Documents/About%20Us/Financial%20Statement06FINAL.pdf</ref>.
Although there is no disclosure of the corporate sponsorship in the annual financial reports and website of Diabetes UK, it's connection to the pharmaceutical industry is more explicit on the [[Strategic Alliance]] website.<ref>http://www.diabetesplanning.org</ref> it is the alliance between pharmaceutical companies such as [[Sanofi-Aventis]], [[GSK]], [[Pfizer]] and Diabetes UK.
 
  
=='Corporate Partners'==
+
Although there is no disclosure of the corporate sponsorship in the annual financial reports and the website of Diabetes UK, its connection to the pharmaceutical industry is more explicit on the [[Strategic Alliance]] website.<ref>http://www.diabetesplanning.org</ref> It is the alliance between pharmaceutical companies such as [[Sanofi-Aventis]], [[GSK]], [[Pfizer]] and Diabetes UK.
 +
According to its website The Strategic Alliance "was established to explore potential joint initiatives that would drive delivery of diabetes policy in order to enhance the quality of diabetes care & improve outcomes for people with diabetes." <ref>http://www.diabetesplanning.org/index.php?country=3</ref> The representative of the charity Bridget Turner described the alliance as being free of commercial interest, "a non-commercial body with labour/funding contributed equally in a four way split between the three pharma companies and the charity".<ref>[http://www.apmhealtheurope.com/story.php?mots=WEBSITE&searchScope=1&searchType=0&numero=1992 New UK charity/pharma funded diabetes website aims to raise disease awareness and funding] APM Health Europe, March 30, 2006</ref> The website of the Strategic Alliance does not provide exhaustive contact information apart from one enquiry email address.
 +
 
 +
==Corporate Partners==
 
[[Sanofi-Aventis Group]]  
 
[[Sanofi-Aventis Group]]  
  
Line 11: Line 13:
  
 
[[Eli Lilly and Company]] Limited
 
[[Eli Lilly and Company]] Limited
 +
 +
[[GlaxoSmithKline]]'s 2001 Annual Report lists Diabetes UK as among the recipients in 2000 of "approximately £100,000" for "medical research".<ref>"[http://www.gsk.com/financial/reports/ar/report/descrip_of_bus/comm_partner/com_partner.html Global community partnerships]", GlaxoSmithKline website, accessed February 2009.</ref>
 +
 +
Diabetes UK is reported to have received financial support from [[Bristol-Myers Squibb]] for the period 2005 to 2007<ref> Bristol-Myers Squibb [http://www.b-ms.co.uk/info-for-patients2.htm Bristol-Myers Squibb and its financial relationship with patient groups and charitable organisations] Accessed 12th February 2008</ref>
  
 
==Affiliations==
 
==Affiliations==
[[Pharmaceutical Services Negotiating Committee]]
+
*[[Pharmaceutical Services Negotiating Committee]]
 +
 
 +
==PR, Lobbying and Business Intelligence firms==
 +
*[[Incisive Health]]<ref> Incisive Health [http://www.incisivehealth.com/clients Clients], accessed 25 June 2015.</ref>
 +
*[[InHouse PR]]
  
 
==Notes==
 
==Notes==
 
<references/>
 
<references/>
 
[[Category:Patient Groups]]
 
[[Category:Patient Groups]]

Latest revision as of 15:00, 25 June 2015

Diabetes UK is a charity working for "people with diabetes, funding research, campaigning and helping people live with the condition. [...]We represent the interests of people with diabetes by lobbying the government for better standards of care and the best quality of life. Diabetes UK spends up to £6.5 million on research".[1] Diabetes UK uses services of Ipsos MORI[2].

Although there is no disclosure of the corporate sponsorship in the annual financial reports and the website of Diabetes UK, its connection to the pharmaceutical industry is more explicit on the Strategic Alliance website.[3] It is the alliance between pharmaceutical companies such as Sanofi-Aventis, GSK, Pfizer and Diabetes UK. According to its website The Strategic Alliance "was established to explore potential joint initiatives that would drive delivery of diabetes policy in order to enhance the quality of diabetes care & improve outcomes for people with diabetes." [4] The representative of the charity Bridget Turner described the alliance as being free of commercial interest, "a non-commercial body with labour/funding contributed equally in a four way split between the three pharma companies and the charity".[5] The website of the Strategic Alliance does not provide exhaustive contact information apart from one enquiry email address.

Corporate Partners

Sanofi-Aventis Group

Lloyds Pharmacy

United Co-op

Eli Lilly and Company Limited

GlaxoSmithKline's 2001 Annual Report lists Diabetes UK as among the recipients in 2000 of "approximately £100,000" for "medical research".[6]

Diabetes UK is reported to have received financial support from Bristol-Myers Squibb for the period 2005 to 2007[7]

Affiliations

PR, Lobbying and Business Intelligence firms

Notes